May 03, 2022
Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer
Media
May 03, 2022
Nordic Nanovector: New Publication Highlights Synergistic Potential of CD37-targeted Radioimmunoconjugate Humalutin® in Combination with the PARP-inhibitor Olaparib
May 03, 2022
Targovax ASA: Invitation to presentation of Targovax’s first quarter 2022 results, Thursday 12 May
April 28, 2022
Targovax ASA: Two ONCOS-102 abstracts accepted for ASCO
April 27, 2022
BONESUPPORT HOLDING AB (publ) – Invitation to conference call and webcast for Interim Report Q1 2022
April 27, 2022
Invitation to presentation of Q1 report
April 26, 2022
Fusion Pharmaceuticals To Present At The 2022 Bloom Burton & Co. Healthcare Investor Conference
April 26, 2022
Targovax to present at 5th Neoantigen Summit Europe in Amsterdam
April 25, 2022
Carisma Therapeutics Announces Appointment Of Michael Klichinsky, PharmD, PhD, As Chief Scientific Officer
April 25, 2022
Priothera Receives FDA clearance of Investigational New Drug (IND) to start Phase 2b/3 study with mocravimod in Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT)